ClinicalTrials.gg
CompletedNCT02183064Updated Jul 8, 2014

Study to Compare Prescription Non-Steroidal Anti-Inflammatory Drug (NSAID) Changes, Health Care Utilization, Efficacy and Safety of Meloxicam 7.5 mg Versus Usual Care Administration of Prescription NSAIDs in a Managed Healthcare Setting in Patients With Osteoarthritis

A Phase 3 interventional study of Meloxicam and NSAID in Osteoarthritis, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-08.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,309
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Osteoarthritis by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Osteoarthritis · Boehringer Ingelheim.

Started
1998
with 3 others
Phase 3
2 of 15
none open now
Registered
8th of 15
by date

Among the 15 studies in Osteoarthritis by Boehringer Ingelheim, this one is one of 4 that started in 1998, is one of 2 in phase 3, and was the 8th registered.

Osteoarthritis

2,975 studies on the registry are indexed under Osteoarthritis; 436 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

None of the 15 studies in Osteoarthritis by Boehringer Ingelheim is open now. The open studies under Osteoarthritis, anywhere →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Osteoarthritis by Boehringer Ingelheim as a file.
02

Study summary

Study to compare the percentage of treatment successes or failures in patients randomized to meloxicam 7.5 mg vs. usual care prescription NSAIDs. Additionally, health care utilization, efficacy and safety of patients in a managed healthcare setting with osteoarthritis (OA) of the hip, knee, hand or spine will be assessed.

03

Conditions studied

  • Osteoarthritis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females over the age of 18
  • The patient, if female and of (i.e. neither surgically sterilized nor ), must be practicing adequate (e.g. intrauterine device, contraceptive pills, Depo-Provera, or implant or double barrier device) for at least three months prior to and for the duration of their trial participation and must have a negative pregnancy test at screening. Abstinence is not considered to be an acceptable method of contraception. (It should be noted that NSAIDs might interfere with the effectiveness of intrauterine devices)
  • The patient must have a documented diagnosis of at least one of the following:

    • Osteoarthritis of the hip
    • Osteoarthritis of the knee
    • Osteoarthritis of the hand or
    • Osteoarthritis of the spine - Patients must have radiographic confirmation of the diagnosis
  • The patient is willing to change or requires a change in current prescription NSAID therapy or requires initiation of prescription NSAID therapy for treatment of OA of the hip, knee, hand or spine
  • The patient intends to remain a member of their present Managed Care Organization (MCO) for the duration of the trial
  • The patient is willing to comply with instructions and to provide written

Exclusion criteria

Exclusion Criteria:

  • The patient has a known or suspected to the trial drugs or their , analgesics, antipyretics or NSAIDS (prescription or over-the-counter)
  • The patient has received an drug or used an investigational device within 30 days prior to entering the trial
  • In the opinion of the investigator the patient has any disease or condition that may result in altered absorption, excess accumulation or impaired metabolism or excretion of the trial medication
  • The patient has a history of recurrent peptic ulcer or history (within the past 6 months) of gastrointestinal perforation, peptic ulceration documented by endoscopy or radiography, symptomatic hiatal hernia requiring daily treatment or any history of a gastrointestinal tract hemorrhage, except simple hemorrhoidal bleeding
  • The patient is currently on coumadin or might be placed on coumadin during the course of the clinical trial
  • Patients with dementia, i.e. incapable of following directions or complying with the study protocol
  • Patients with co-existing rheumatological disorders including rheumatoid arthritis
  • The patient has previously participated in this trial
  • Patients with coexisting fibromyalgia or ankylosing spondylitis
  • Patient is pregnant or lactating
  • Patient has severe hepatic failure
  • Patient has non-dialysed renal failure
  • Patient has history of GI bleed within the past 6 months
  • Patient has history of cerebrovascular bleeding or other bleeding disorders
  • Patient is receiving concomitant lithium, heparin or ticlopidine therapy
  • Patient has a history of leukopenia (White Blood Cell count \< 3500/mm³)
  • The patient has a history of count below the lower limit of normal or has a documented abnormal (PT) or partial thromboplastin time (PTT)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,309 participants (actual)

Study arms

  • Experimental
    Meloxicam

    Drug: Meloxicam

  • Active comparator
    Usual care prescription NSAID

    Drug: NSAID

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of treatment successes and failures in patients randomized to meloxicam 7.5 mg vs.usual care prescription NSAIDs

    Time frame: up to 6 month

Secondary outcomes

  1. Investigator's Global Assessment of Disease Activity (Likert)

    Time frame: Screening (Day 0), after six month (Day 180)

  2. Patient's overall Assessment of pain over the past week on a visual analogue scale (VAS)

    Time frame: Day 0, 30, 60, 90, 120, 150, 180

  3. Patient's Assessment of Health Status (VAS)

    Time frame: Day 0, 30, 60, 90, 120, 150, 180

  4. Patient's Assessment of Satisfaction of Health

    Time frame: Day 0, 30, 60, 90, 120, 150, 180

  5. Utility Index (VAS)

    Time frame: Day 0, 30, 60, 90, 120, 150, 180

  6. Western Ontario and Mc Master University Osteoarthritis Index (WOMAC)

    Time frame: Day 0, 30, 60, 90, 120, 150, 180

  7. Medication Compliance

    Time frame: Day 30, day 180

  8. Disability Index

    Time frame: Screening (Day 0), after six month (Day 180)

  9. Permanent Discontinuation of Study Medication related to lack of efficacy

    Time frame: up to day 180

  10. Incidence and intensity of adverse events

    Time frame: from day 30 until day 180

  11. Permanent Discontinuation of Study Medication related to adverse event

    Time frame: from day 30 until day 180

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 1998 and a primary completion of Nov 2000. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2014
First posted
Jul 8, 2014
Start
Oct 1998
Primary completionActual
Nov 2000
Last update
Jul 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02183064
Responsible party
Sponsor
First posted
Jul 8, 2014
Start date
Oct 1998
Primary completion
Nov 2000
Last update
Jul 8, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meloxicam

Start the discussion